Advertisement

Advertisement

2020 San Antonio Breast Cancer Symposium

Breast Cancer

Can Postoperative Whole-Breast Irradiation Be Safely Omitted in Older Women With Low-Risk Breast Cancer?

Omitting postoperative radiotherapy with whole-breast irradiation may not compromise 10-year overall survival or increase the risk of developing metastasis in most women 65 years and older with low-ri...

breast cancer

Ann H. Partridge, MD, MPH, on ER+, HER2– Breast Cancer: More Effective Treatments Needed

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the ALTERNATE trial on response to neoadjuvant chemotherapy in postmenopausal women with clinical stage II or III est...

breast cancer

Elizabeth A. Mittendorf, MD, PhD, on Her Plenary Lecture: Local Regional Management Following Neoadjuvant Therapy

Elizabeth A. Mittendorf, MD, PhD, of Brigham and Women’s Hospital, summarizes her plenary talk, which featured the uncertainties in treatment knowledge: excision of postchemotherapy calcifications; th...

Breast Cancer

CTC Enumeration Predicts Survival Early in Treatment of Metastatic Breast Cancer

The number of circulating tumor cells (CTCs) assessed at baseline and at about 1 month after cancer-directed treatment was strongly associated with overall survival in patients with metastatic breast ...

Breast Cancer

RxPONDER: Many Postmenopausal Patients With Node-Positive Breast Cancer Can Avoid Chemotherapy

Just in are the results of the SWOG S1007 RxPONDER trial, which evaluated the benefit of chemotherapy in women with early-stage hormone receptor–positive, HER2-negative breast cancer and node-positiv...

breast cancer

Sibylle Loibl, MD, on HR+ HER2– Primary Breast Cancer: Palbociclib and Endocrine Therapy

Sibylle Loibl, MD, of the German Breast Group, discusses the first phase III results from the PENELOPE-B study of palbociclib combined with endocrine therapy in patients with hormone receptor–positive...

breast cancer
genomics/genetics
immunotherapy

Joyce V. Lee, PhD, on Triple-Negative Breast Cancer: MYC as a Predictor of Treatment Response

Joyce V. Lee, PhD, of the University of California, San Francisco, discusses data that suggest the MYC oncogene may indicate whether a patient with triple-negative breast cancer will respond to immuno...

breast cancer

Roisin M. Connolly, MD, on HR+ Advanced Breast Cancer: Endocrine Therapy and Entinostat

Roisin M. Connolly, MD, of University College Cork, discusses phase III results from the E2112 trial, which showed exemestane plus entinostat did not improve survival in aromatase inhibitor–resistant ...

breast cancer

Lee S. Schwartzberg, MD, on HER2– HR+ Breast Cancer: Tesetaxel and Capecitabine

Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase III results from the CONTESSA study, which showed that an all-oral regimen of tesetaxel plus a reduced dose of capecitabine signific...

breast cancer
immunotherapy

Sara A. Hurvitz, MD, on Triple-Negative Breast Cancer: Sacituzumab Govitecan and Chemotherapy

Sara A. Hurvitz, MD, of the David Geffen School of Medicine at UCLA, discusses phase III data from the ASCENT study of the antibody-drug conjugate sacituzumab govitecan vs chemotherapy in patients wit...

breast cancer
supportive care

Patricia A. Ganz, MD, on Younger Breast Cancer Survivors: Managing Depression

Patricia A. Ganz, MD, of the University of California, Los Angeles, discusses study findings that showed mindfulness meditation and survivorship education may effectively reduce depression and related...

breast cancer

Joseph A. Sparano, MD, on HR+, HER2– Breast Cancer: Individualizing Prognosis and Predicting Treatment Success

Joseph A. Sparano, MD, of the Montefiore Medical Center and Albert Einstein College of Medicine, discusses the development and validation of a tool that integrates the 21-gene recurrence score and cli...

breast cancer

Nadia Harbeck, MD, on Early Breast Cancer: Endocrine Therapy After Preoperative Treatment

Nadia Harbeck, MD, of the University of Munich, discusses the first outcome data from the phase III ADAPT HR+/HER– trial, which combined both static and dynamic biomarkers to optimize the adjuvant the...

Breast Cancer

SABCS 2020: CTC Enumeration May Be Predictive of Survival During Treatment for Metastatic Breast Cancer

The number of circulating tumor cells (CTCs) assessed at baseline and about 1 month after cancer-directed treatment was associated with overall survival in patients with metastatic breast cancer, acco...

Breast Cancer
Immunotherapy

SABCS 2020: Patient-Reported Outcomes From the Phase III IMpassion031 Trial

Adding an immune checkpoint inhibitor to a standard chemotherapy regimen for patients with early-stage triple-negative breast cancer did not affect patients’ ability to perform day-to-day activities m...

Breast Cancer

SABCS 2020: New Prognostic Tool to Determine Individual Risk of Distant Recurrence, Benefit of Adjuvant Chemotherapy in Early Breast Cancer

In a study presented at the 2020 San Antonio Breast Cancer Symposium (Abstract GS4-10) and concurrently published in the Journal of Clinical Oncology, Joseph A. Sparano, MD, and colleagues described t...

Breast Cancer

SABCS 2020: RxPONDER Study Shows Postmenopausal Patients With Node-Positive Breast Cancer May Be Able to Avoid Chemotherapy

Just in are the results of the SWOG S1007 RxPONDER trial, which evaluated the benefit of chemotherapy in women with early-stage, hormone receptor (HR)-positive, node-positive breast cancer. Based on t...

Breast Cancer

SABCS 2020: Follow-up Data From monarchE Show Continued Abemaciclib Benefit in High-Risk, HR-Positive, HER2-Negative Breast Cancer

Extended follow-up results from the phase III monarchE trial showed that adding the cyclin-dependent kinase inhibitor abemaciclib to standard adjuvant endocrine therapy continued to improve invasive d...

Breast Cancer
Survivorship

SABCS 2020: Can Mindfulness Meditation and Survivorship Education Help to Reduce Depression in Young Breast Cancer Survivors?

New research showed that behavioral interventions—mindfulness meditation and survivorship education classes—may be effective in reducing depressive symptoms in younger breast cancer survivors. This pa...

breast cancer

Debra A. Pratt, MD, on Time to Completion of Breast Cancer Treatment and Survival

In her recent study, Debra A. Pratt, MD, of the Cleveland Clinic, showed that when breast cancer treatment using any of three modalities takes longer than 38 weeks, it is associated with a decrease in...

breast cancer

Chirag Shah, MD, on Assessing DCIS Recurrence Risk

Chirag Shah, MD, of the Cleveland Clinic, discusses the impact of DCISionRT testing on radiation therapy recommendations for patients with ductal carcinoma in situ following lumpectomy. His study foun...

Breast Cancer
Symptom Management
Issues in Oncology

SABCS 2020: Patients With Breast Cancer Undergoing Radiotherapy May Have Underrecognized Side Effects

Among patients with breast cancer treated with radiotherapy, symptoms were commonly underrecognized in reports of pain, pruritus, edema, and fatigue, with younger patients and Black patients having si...

Breast Cancer
Pain Management
Issues in Oncology

SABCS 2020: Opioid and Sedative-Hypnotic Use After Mastectomy With Reconstructive Surgery

Women who undergo mastectomy with reconstructive surgery as part of breast cancer treatment may face the risk of persistent use of opioids and sedative-hypnotic drugs, according to data presented by J...

Breast Cancer
Survivorship

SABCS 2020: Meta-analysis of Pregnancy Outcomes in Breast Cancer Survivors

A large meta-analysis of breast cancer survivors of childbearing age indicated that they are less likely than the general public to become pregnant and may face a higher risk of certain complications,...

Breast Cancer

SABCS 2020: Radiotherapy Omission After Breast-Conserving Surgery for Older Patients With HR-Positive Breast Cancer

Patients aged 65 or older with hormone receptor (HR)-positive breast cancer who did not receive radiation therapy after breast-conserving surgery had higher rates of local recurrence but similar 10-ye...

Advertisement

Advertisement



Advertisement